placebo treatment. Dispensing of spironolactone or placebo was done by the hospital pharmacist so that neither patient nor investigator was aware of the treatment received. The placebo was an identical tablet to spironolactone with the active principle omitted. Patients were reassessed three and six months after starting treatment by repeats of the baseline investigations.
Placebo Response
The results in the group of patients taking placebo stress the need for care in assessing the value of drugs in benign prostatic hypertrophy. The symptom score of patients taking placebo for six months was less in 76 %, frequency was less in 71 % and nocturia in 62%. Digital prostate size was thought to be smaller in 15 out of 21 patients, larger in 5 and unchanged in one, but the overall change in prostate size of 09 cm was not significant statistically. Radiological measurements also changed after placebo, probably due to the subjective interpretation of the radiographs. In particular, there was significant decrease of residual urine measured by planimetry but residual urine measured by catheterization was unchanged (Table 1) . Maximal intravesical pressure increased significantly during the six months of placebo (P=0-02). This could reflect real deterioration or conscious straining. Other studies show that this measurement does not differentiate patients with benign prostatic hypertrophy from normals (Castro & Griffiths 1972 ); furthermore, it requires complicated apparatus and is not suitable for repeated measurements. In contrast, urinary flow rate can be easily measured; it was not affected by placebo and is the best objective measurement reflecting real change.
Conclusions
These studies show the importance of doubleblind, controlled trials in the clinical assessment of drugs thought to be useful in the treatment of benign prostatic hypertrophy. Many measurements used for assessing the patients changed when placebo was given and the most useful objective measurements were the maximal urinary flow rate and the residual urine measured by catheterization; these should be included in any trial of 'pills for the prostate'. Testosterone was first isolated in the mid 1930s, and since then has been regarded as the principal androgenic hormone responsible for developing and maintaining the activity of male accessory sex organs, such as the prostate. Recent studies in rats have qujestioned this concept because administration of tritium-labelled testosterone did not result in the accumulation of testosterone in the ventral prostatic tissue, but of a metabolite of this steroid, 5a-dihydrotestosterone (5aT) ). Furthermore, 'receptor' proteins which specifically bound 5aT were demonstrated in the cytoplasm of rat prostatic cells, and these were absent from non-target tissues that were examined. 5aT was probably transferred to the nuclei of prostatic cells by a process which involved these receptors.
These are important new observations, and some attempt must be made to relate them to the problems of human prostatic disease.
Studies on rat prostatic tissue have been carried out on normal animals, and it is difficult to compare these with studies of normal human tissue as this is only obtainable from autopsy specimens and prostates removed at total cystoprostatectomy. However, our studies have shown that the metabolism of testosterone in benign hyperplastic prostatic tissue in humans is similar to that in rats. Tritium-labelled testosterone (10 ,uCi) was administered intravenously to men undergoing open prostatectomy, and the principal radio-labelled steroid isolated from the removed tissue was 5aT (Pike et al. 1970 ). These observations relate well to those of who found that the concentration of 5aT was on average five times greater in hyperplastic than in normal prostatic tissue in men, and that it was sited mostly in the peri-urethral zone of the gland. Possibly 5aT plays a role in the etiology of benign hyperplasia of the prostate in humans; the observation that some degree of prostatic hyperplasia was also induced when young castrated dogs were treated with 5aT (Gloyna et al. 1970) supports this idea.
In relation to these observations the tissue culture studies of Baulieu and his colleagues (Baulieu & Robel 1970 , Lasnitzki 1970 are particularly relevant. They showed that not only did testosterone and 5aT play some role in the maintenance of the functional integrity of rat prostate cells in culture, but also that other testosterone metabolites, the 5a-androstanediols which are also found in prostatic tissue, may control some aspects of cell metabolism. This suggests that testosterone and its various metabolites may possibly each have a particular function in the prostate, and that a change in the balance or relative concentrations of these steroids could be concerned with the induction of hyperplasia or neoplasia. A possible role of aestrogens in the control of these metabolic patterns requires further investigation.
Experiments conducted in our laboratories with rat, canine and human prostatic tissue in culture indicated that aestrogens affected testosterone metabolism by the tissue. CEstradiol-1 7p and diethylstilbestrol decreased both the uptake of radioactive testosterone by the tissue and the 5aT formed. The amount of radioactive 5aT isolated from nuclear preparations of culture tissue decreased when either oestradiol-17, or diethylstilbcestrol was present in the medium. Moreover, an identical effect was obtained with dihydrodibutylstilbeestrol, an analogue of diethylstilboestrol. This compound, synthesized in our laboratories , has 0-1 % of the cestrogenic activity of ostradiol-17P, and further studies on its biological activity in the rat and dog are currently in progress to assess any possible application to the treatment of prostatic dysfunction in men. One interesting series of experiments in this respect is concerned with the activity of the nuclear enzyme system, DNA polymerase, isolated from human prostatic tissue. When this isolated enzyme system was incubated with the appropriate co-factors, it was shown that 5aT and testosterone were capable of stimulating the activity of certain of the enzyme preparations from human hyperplastic prostatic tissue. Conversely, both diethylstilbeestrol and dihydrodibutylstilbeestrol inhibited the enzyme system isolated from both hyperplastic and malignant prostatic tissue, whereas other alkyl substituted derivatives of stilboestrol, such as dipropylstilboestrol and dibutylstilbeestrol, had little or no effect. It is possible, therefore, that dihydrodibutylstilboestrol exercises a direct action on this nuclear enzyme system in vivo, and further studies are in progress to ascertain the mechanism of this inhibitory effect and any possible application to the treatment of benign hyperplasia and carcinoma of the prostate in men. The low cestrogenicity of this compound could be a crucial factor in any practical considerations, particularly in view of the recent reservations about the place of diethylstilboestrol in the treatment of prostatic cancer (Arduino et a!. 1967).
Dr A G Pitchford (Schering Chemicals Limited, Burgess Hill, Sussex) Gestronol Hexanoate (SHF582) and Benign Prostatic Hypertrophy Interest in the possible value of progestogens in benign prostatic hypertrophy was first aroused by a trial reported by Geller et al. in 1965. The preparation used was 17a-hydroxyprogesterone caproate (Primolut Depot) and objective improvements were described in 3 of the 10 patients studied. Histologically, glandular atrophy was demonstrated in prostatic biopsy specimens obtained two or more months after the start of treatment.
At the time of Geller's report a further, more potent, derivative of hydroxyprogesterone had been synthesized, 17a-hydroxy-19-nor-progesterone caproate (gestronol hexanoate BP; Depostat Schering). The comparative activities of progesterone, hydroxyprogesterone caproate and gestronol hexanoate are set out in Table 1 . From this it will be noted that the latter preparation has some 25 times the potency of the one which Geller used. Both preparations have a
